Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Should You Sell?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped down before the market opened on Thursday . The stock had previously closed at $32.44, but opened at $30.88. Ascentage Pharma Group International shares last traded at $30.88, with a volume of 289 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on AAPG shares. Oppenheimer began coverage on shares of Ascentage Pharma Group International in a research note on Thursday. They set an “outperform” rating and a $45.00 price objective on the stock. Truist Financial set a $51.00 price objective on Ascentage Pharma Group International in a report on Monday, November 24th. BTIG Research assumed coverage on Ascentage Pharma Group International in a research report on Monday, November 10th. They issued a “buy” rating and a $50.00 target price for the company. Finally, Piper Sandler initiated coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, November 5th. They set an “overweight” rating and a $48.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Ascentage Pharma Group International has a consensus rating of “Buy” and an average price target of $48.50.

Ascentage Pharma Group International Stock Performance

The firm has a 50-day simple moving average of $34.34 and a 200-day simple moving average of $36.41. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53.

Institutional Trading of Ascentage Pharma Group International

Several large investors have recently added to or reduced their stakes in the business. Chevy Chase Trust Holdings LLC purchased a new stake in Ascentage Pharma Group International during the second quarter valued at approximately $227,000. Tema Etfs LLC bought a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at $610,000. XY Capital Ltd increased its stake in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares in the last quarter. UBS Group AG increased its stake in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Ascentage Pharma Group International in the 3rd quarter worth $96,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.